Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

MrPeanutEsquire Jul. 15 at 3:37 PM

$PFE What is this bluish yellow color? What is happening? Doesn't the market know its almost noon?

1 · Reply

STOCKPICKERTRADER Jul. 15 at 3:17 PM

$PFE pushed above the Point of Control on the Daily Chart in addition to being above last 3-weeks action and the 20dma. Gap fill target around 25.9x area that would be above 50dma and also the 200dma base area for a much more bullish disposition from there. Easy peezy....

0 · Reply

Oiljunkie Jul. 15 at 3:13 PM

$PFE

0 · Reply

MrPeanutEsquire Jul. 15 at 2:45 PM

$PFE Its doing the thing that Lilly does. Weird

1 · Reply

PFElinepfrenzy1990 Jul. 15 at 2:39 PM

Green $PFE? Sus. As usual.

1 · Reply

Micheal_Pothead Jul. 15 at 2:36 PM

$PFE I say again, why can’t you just be normal

0 · Reply

GCTRADER88 Jul. 15 at 2:24 PM

$PFE technically ready to move to $28.74 resistance but may need a few weeks... also may happen suddenly if news

0 · Reply

ProTraderColin Jul. 15 at 2:21 PM

$PFE trying once again to break out over the 20 EMA

0 · Reply

jrh34 Jul. 15 at 2:01 PM

$PFE is up nicely today, are they part of the direct offering here with $CRDF time will tell.

0 · Reply

TraderDaKing Jul. 15 at 1:07 PM

$ELTP $LLY $JNJ $PFE $GME Elite Pharmaceuticals is the next MEME Pharma stock in play. There are talks all over about SequestOX... Something is going on. Its on their website. News coming Soon. Elite Pharmaceuticals Inc. https://elitepharma.com

1 · Reply

Pfizer price target lowered to $30 from $34 at BMO Capital

2026-07-13T11:06:16.000Z - 2 days ago

Pfizer price target lowered to $35 from $36 at Guggenheim

2026-07-10T15:30:20.000Z - 5 days ago

Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC

MRK

Jul 10, 2026, 11:23 AM EDT - 5 days ago

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

2026-07-10T10:30:21.000Z - 5 days ago

Pfizer price target lowered to $26 from $27 at BofA

2026-07-09T18:30:15.000Z - 5 days ago

Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says

AZN

2026-07-08T12:15:37.000Z - 7 days ago

Pfizer price target lowered to $28 from $30 at JPMorgan

2026-07-07T15:54:25.000Z - 8 days ago

Pfizer (PFE) Stock Bounces Back After an Analyst Downgrade

Jul 6, 2026, 10:00 AM EDT - 9 days ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

2026-07-06T09:50:29.000Z - 9 days ago

Pfizer downgraded to Hold from Buy at HSBC

Jun 29, 2026, 4:43 PM EDT - 15 days ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Jun 29, 2026, 1:20 AM EDT - 16 days ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 24, 2026, 3:52 PM EDT - 20 days ago

Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 2:10 PM EDT - 20 days ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 10:51 AM EDT - 21 days ago

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 23, 2026, 12:10 PM EDT - 22 days ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 10:00 AM EDT - 22 days ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 22, 2026, 4:43 PM EDT - 22 days ago

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:30 PM EDT - 22 days ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 2:32 PM EDT - 22 days ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Jun 18, 2026, 6:52 AM EDT - 27 days ago

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:45 AM EDT - 27 days ago

Pfizer Announces Chief Financial Officer Transition

Jun 10, 2026, 7:56 AM EDT - 5 weeks ago

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 9, 2026, 2:07 PM EDT - 5 weeks ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Jun 9, 2026, 9:20 AM EDT - 5 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

Jun 9, 2026, 3:20 AM EDT - 5 weeks ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 6:49 AM EDT - 5 weeks ago

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:45 AM EDT - 5 weeks ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 6, 2026, 11:00 AM EDT - 5 weeks ago

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 5 weeks ago

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 5 weeks ago

Pfizer Press release: Study update

Jun 6, 2026, 9:06 AM EDT - 5 weeks ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:00 AM EDT - 5 weeks ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 4, 2026, 10:00 AM EDT - 5 weeks ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 6:40 AM EDT - 5 weeks ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Jun 3, 2026, 2:00 PM EDT - 5 weeks ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 31, 2026, 8:00 AM EDT - 6 weeks ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 30, 2026, 9:22 AM EDT - 6 weeks ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA

May 30, 2026, 8:00 AM EDT - 6 weeks ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 29, 2026, 8:00 AM EDT - 6 weeks ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 28, 2026, 11:10 PM EDT - 6 weeks ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 7:19 PM EDT - 6 weeks ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:00 PM EDT - 6 weeks ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 6 weeks ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 27, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 20, 2026, 9:00 AM EDT - 2 months ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20, 2026, 5:08 AM EDT - 2 months ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:05 AM EDT - 2 months ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 18, 2026, 8:00 AM EDT - 2 months ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 14, 2026, 2:22 PM EDT - 2 months ago

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

DGX MO CL

May 13, 2026, 6:45 AM EDT - 2 months ago

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 12, 2026, 8:00 AM EDT - 2 months ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN RIGL

May 12, 2026, 7:00 AM EDT - 2 months ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVN

May 5, 2026, 4:09 PM EDT - 2 months ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:02 PM EDT - 2 months ago

Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 11:30 AM EDT - 2 months ago

3 Dividend Stocks for May 2026

SYY WSO

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Slides: Q1 2026

May 5, 2026, 8:35 AM EDT - 2 months ago

Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 7:23 AM EDT - 2 months ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:06 AM EDT - 2 months ago

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

May 5, 2026, 7:05 AM EDT - 2 months ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS

May 5, 2026, 6:55 AM EDT - 2 months ago

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

MrPeanutEsquire Jul. 15 at 3:37 PM

$PFE What is this bluish yellow color? What is happening? Doesn't the market know its almost noon?

1 · Reply

STOCKPICKERTRADER Jul. 15 at 3:17 PM

0 · Reply

Oiljunkie Jul. 15 at 3:13 PM

$PFE

0 · Reply

MrPeanutEsquire Jul. 15 at 2:45 PM

$PFE Its doing the thing that Lilly does. Weird

1 · Reply

PFElinepfrenzy1990 Jul. 15 at 2:39 PM

Green $PFE? Sus. As usual.

1 · Reply

Micheal_Pothead Jul. 15 at 2:36 PM

$PFE I say again, why can’t you just be normal

0 · Reply

GCTRADER88 Jul. 15 at 2:24 PM

$PFE technically ready to move to $28.74 resistance but may need a few weeks... also may happen suddenly if news

0 · Reply

ProTraderColin Jul. 15 at 2:21 PM

$PFE trying once again to break out over the 20 EMA

0 · Reply

jrh34 Jul. 15 at 2:01 PM

$PFE is up nicely today, are they part of the direct offering here with $CRDF time will tell.

0 · Reply

TraderDaKing Jul. 15 at 1:07 PM

1 · Reply

BarkingPuppy Jul. 15 at 12:55 PM

$AMC $BYND $PFE $TSLA $SPACX Elite is in play Blue horseshoe loves ELTP stock. Next big thing in Pharma .

0 · Reply

BioRich Jul. 15 at 12:45 PM

$GUTS "There is no question that what we are seeing is going to be highly, highly, statistically significant if it continues in the pivotal trial." Fractyl Health CEO, Harith Rajagopalan, M.D., Ph.D., Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $GPCR $VKTX $PFE

1 · Reply

jrh34 Jul. 15 at 12:42 PM

$CRDF yep, a chess move. NMS needs to decide whether to take $10 million in a settlement or spend another $10 million in legal fees to match $CRDF. I want to know who's the institutional investor willing to kick in $9 million to bank roll this - that will tell us how this will likely turn out. If it's $PFE, then yea this is very bullish.

0 · Reply

jrh34 Jul. 15 at 12:29 PM

$CRDF interesting, management investing at a higher price of $1.435, and only raising $10 million? Never seen that deal before. My sense is this is gamesmanship against NMS. Essentially giving $CRDF another $10 million to grind down NMS. Could $PFE be the buyer of the direct offering?

1 · Reply

GeneralGainz Jul. 15 at 11:47 AM

$SPRO $GSK $PFE The more you know!

0 · Reply

nimii Jul. 15 at 8:19 AM

$PFE

0 · Reply

dom04 Jul. 15 at 3:32 AM

$PFE reversal ingo the 25's? Long swing trade?

1 · Reply

brainless Jul. 15 at 1:39 AM

$PFE can’t wait for this to turn around. Been loading the boat for a while now

1 · Reply

EthanH199 Jul. 14 at 11:45 PM

$PFE

0 · Reply

GordoHLYK13 Jul. 14 at 10:56 PM

$IGC Captain “Sully” Sullenberger’s heartbreaking Alzheimer’s diagnosis is another reminder that this disease touches millions of families and highlights the urgent need for better treatments. While no one benefits from news like this, increased public awareness often drives greater attention, funding, and investor interest in companies developing Alzheimer’s therapies. With IGC Pharma’s Phase 2 CALMA trial targeting Alzheimer’s-related agitation nearing a major readout, the spotlight on this disease could put IGC on more investors’ radar at a critical time. Awareness fuels urgency, and urgency can fuel innovation. $MRNA $LLY $PFE https://www.foxnews.com/health/miracle-hudson-hero-captain-sully-sullenberger-reveals-alzheimers-diagnosis

0 · Reply

mikesterz7 Jul. 14 at 9:30 PM

$CELC $PFE 🚨🚨🚨 The FDA approved gedatolisib in combination with cancer drug fulvestrant, with or without Pfizer’s palbociclib. This approval gives the company its first marketed product and transitions it from a pure development-stage firm to one with a commercial opportunity

0 · Reply

STOCKPICKERTRADER Jul. 14 at 9:29 PM

$PFE FYI - Bourla has some 772,038 shares directly owned so skin is in the game, though lacking results overdue by the company imho https://archive.fast-edgar.com/20260713/A9LZD22CO2225JZV22292ZZZMCSVZ2O2Z682/

1 · Reply

Market Cap	139.52B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	7.90
Forward PE	8.17
Profit Margin	12.42%
Debt to Equity Ratio	0.71

Volume	40,863,300
Avg Vol	41,914,176
Day's Range	N/A - N/A
Shares Out	5.70B
Stochastic %K	57%
Beta	0.35
Analysts	Sell
Price Target	$28.80